MARKET

SINT

SINT

SINTX Technologies Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.965
+0.035
+1.81%
Opening 09:37 01/25 EST
OPEN
1.960
PREV CLOSE
1.930
HIGH
1.970
LOW
1.950
VOLUME
130.69K
TURNOVER
--
52 WEEK HIGH
3.300
52 WEEK LOW
0.2800
MARKET CAP
50.21M
P/E (TTM)
-0.8859
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Top Penny Stocks To Buy Now? Analyst Have Targets Up To 386% On 5
Jan 13, 2021 (Penny Stocks via COMTEX) -- Analysts Rate These Penny Stocks A Buy Right Now The thought of making money with penny stocks is always the...
Penny Stocks · 01/13 13:55
SINTX Technologies Looks Ahead to 2021 Opportunities and Beyond
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) ("SINTX" or the "Company"), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, will celebrate its 25 year in existence in 2021. The Company has a s...
GlobeNewswire · 01/06 14:00
SINTX Technologies Looks Ahead to 2021 Opportunities and Beyond
GlobeNewswire · 01/06 14:00
SINTX Technologies Q3 EPS $(0.11) Up From $(0.68) YoY, Sales $100.00K Down From $200.00K YoY
SINTX Technologies (NASDAQ:SINT) reported quarterly losses of $(0.11) per share. This is a 83.82 percent increase over losses of $(0.68) per share from the same period last year. The company reported $100.00 thousand in
Benzinga · 11/16/2020 19:32
SINTX Technologies Shares Q3 Business Update and Identifies Growth Opportunities for 2021
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) ("SINTX" or the "Company"), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, shared details on its Q3 business update and new business opportunities ahead.
GlobeNewswire · 11/16/2020 19:30
SINTX Technologies Shares Q3 Business Update and Identifies Growth Opportunities for 2021
SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, shared details on ...
GlobeNewswire · 11/16/2020 19:30
SINTX Technologies Shares Q3 Business Update and Identifies Growth Opportunities for 2021
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) ("SINTX" or the "Company"), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, shared details on its Q3 business update and new business opportunit...
GlobeNewswire · 11/16/2020 19:30
SINTX Technologies Shares Q3 Business Update and Identifies Growth Opportunities for 2021
SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, shared details on its Q3 business update and new business opportunities ahead. Throughout the pandemic, SINTX has continued to address the impact of COVID-19 on its business operations. The Company has avoided layoffs and invested in the safety of its employees through new protocols and work from home policies. As such, SINTX has been able to maintain business operations as usual in Q3, except for the reduction in spine sales which we discuss below.“Despite an unpredictable year, we feel fortunate that our business has been able to minimize the impact of COVID-19,” said Dr. Sonny Bal, President, and CEO, SINTX Technologies. “Our business has been able to hire new employees, expand necessary research and development, and engage with new customers to create a variety of applications using our silicon nitride. As one example, we manufactured and shipped industrial prototype parts for the first time in our history. We’re looking forward to additional growth in 2021 and aggressively pursuing the opportunities in front of us.”Third Quarter Financial ResultsSINTX reported revenue of $0.1 million for the three months ended September 30, 2020, and $0.5 million for the nine months ended September 30, 2020. Generally accepted accounting principles (GAAP) basic net loss for the three months ended September 30, 2020, was $0.11 per share, compared to a basic net loss of $0.68 per share for the three months ended September 30, 2019. For the nine months ended September 30, 2020, the Company reported a GAAP basic net loss of $0.39 per share, compared to a basic net loss of $3.00 per share for the nine months ended September 30, 2019. The Company’s cash and cash equivalents were $27.1 million as of September 30, 2020, an increase of $25.3 million from December 31, 2019.The Company shipped one aerospace prototype order in the quarter. The balance of the revenue came from sales of production and prototype components to CTL Amedica.SINTX reported a significant reduction in the number of remaining unconverted preferred shares from the May 2018 and February 2020 offerings as well as in the number of unexchanged warrants. The details can be found in the 10-Q.Medical Devices UpdateOverall, revenue from medical devices was predictably down due to hospital restrictions on elective surgeries taking place during the COVID-19 pandemic. Those restrictions are expected to continue to hurt US sales to CTL Amedica of the Valeo product line. However, CTL Amedica has gained regulatory clearance in Taiwan and future sales to CTL Amedica are anticipated in support of the expected growth from that new opportunity. Furthermore, SINTX and CTL Amedica have been collaborating on the development of new spinal implants made from monolithic silicon nitride and SINTX’s Silicon Nitride-PEEK composite, and sales from those products are expected in 2021.The COVID-19 pandemic has also impacted SINTX’s collaborative efforts in the dental market. However, SINTX’s partners have recently renewed contact and those projects are moving forward. These projects are looking both at monolithic silicon nitride implants as well as coatings of silicon nitride on titanium implants. Revenue from these opportunities is not expected for several years as silicon nitride is a novel material in dental applications, and would have a lengthy regulatory pathway to navigate.SINTX has previously referenced a Material Transfer Agreement with a global medical device manufacturer and this project is also still active. Progress has been impacted by the COVID-19 pandemic as well as by the Company’s emphasis on research and development of novel antipathogenic applications for the Company’s silicon nitride.SINTX added a new U.S. Patent for antibacterial applications of silicon nitride to its technology IP portfolio in Q3. The issued US Patent 10,806,831 broadly covers a variety of biomedical implants wherein the Company’s silicon nitride is applied to improve the antibacterial characteristics of the implant. The first composite product protected under this patent has already been developed and is expected to be commercialized in 2021.The Company believes there are significant future revenue-generating opportunities in the medical device market. In support of that belief, Michael Marcroft was recently hired as a Vice President of Business Development to identify and grow new opportunities in this market. Silicon nitride’s twelve years of successful outcomes in spinal fusion surgery provide a solid foundation for new medical device applications.Non-Medical Product Opportunities AheadSINTX has experienced growth of customer interest in antipathogenic silicon nitride applications. The Company is in active product development discussions with automotive, IT device, face mask, and air filter manufacturers. SINTX’s partnership with O2TODAY to develop a “catch-and-kill” mask that will inactivate respiratory viruses and bacteria continues to progress and is in the manufacturing process development stage. SINTX continues to prioritize the product development of antipathogenic applications through workforce expansion, acquisition of prototype manufacturing and supporting laboratory equipment, and the development of test protocols to assess the antipathogenic properties of new products.SINTX has gained the ability to enter the aerospace and defense markets through its recently announced AS9100D certification, which enables SINTX to supply components directly to these industries. The certification means that SINTX now meets the highly stringent standards of these industries and is listed in the OASIS database, used by aerospace suppliers like Boeing, Lockheed Martin, Raytheon, United Technologies, North Grumman, and the United States military. The Company has received orders for and shipped prototype components to companies in this industry.With new partnership opportunities in place and a shift in business focus toward antipathogenic applications, SINTX has decided not to pursue its previously-announced relationship with Nissin.Research & Development UpdatesIn prior years, SINTX made a substantial investment to confirm and understand the osteogenic and antipathogenic properties of the Company’s silicon nitride. The Company has now pivoted towards an R&D investment strategy that is focused on developing products for new markets that leverage these properties.Where appropriate, SINTX has sought additional funding through highly-competitive external grant opportunities. Although no awards have been received to-date, SINTX’s solid financial condition means that this has not impacted the pace of its research and development activities.“Our focus going into 2021 is to develop and commercialize silicon nitride-embedded fabrics for a variety of applications,” said Dr. Bal. “Another focus is the commercialization of our polymer-silicon nitride composite technology. The third area of focus is the development of silicon nitride coatings on titanium. All of these areas of focus target multiple opportunities in the medical as well as the non-medical markets. In addition, we are aggressively targeting the industrial markets for silicon nitride, including selected strategic opportunities in that space. We are well-capitalized to make the necessary investments in personnel and equipment to generate new revenues.”About SINTX Technologies, Inc.SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered, ISO 9001:2015 certified, ISO 13485:2016 certified, and AS9100D certified manufacturing facility.For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: incorporation of silicon nitride into personal protective equipment may not be safe or effective; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.Business Inquiries for SINTX: SINTX Technologies 801.839.3502 IR@sintx.comMedia Inquiries for SINTX: Amanda Barry Associate Director, Content and PR The Summit Group abarry@summitslc.com
GlobeNewswire · 11/16/2020 19:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SINT. Analyze the recent business situations of SINTX Technologies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SINT stock price target is 4.375 with a high estimate of 4.500 and a low estimate of 4.250.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 348.23K
% Owned: 1.36%
Shares Outstanding: 25.55M
TypeInstitutionsShares
Increased
3
12.46K
New
15
256.48K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.36%
Healthcare Equipment & Supplies
+0.54%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
B. Sonny Bal
Chief Operating Officer
David O'Brien
Chief Technology Officer
Bryan McEntire
Vice President/Director of Sales/Director of Marketing
Dana Lyons
Vice President - Business Development
Michael Marcroft
Independent Director
Mark Froimson
Independent Director
Eric Stookey
Independent Director
David Truetzel
Independent Director
Jeffrey White
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SINT
SINTX Technologies, Inc., formerly Amedica Corporation, is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company is incorporating its silicon nitride technology into components for use in total hip and knee replacement product candidates. The Company markets and sells its products to surgeons and hospitals in the United States, and certain markets in Europe and South America. The Company produces silicon nitride for use in its commercial products and product candidates in the various forms, such as solid silicon nitride, porous silicon nitride, composite silicon nitride and silicon nitride coating.
More

Webull offers kinds of SINTX Technologies Inc stock information, including NASDAQ:SINT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SINT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SINT stock methods without spending real money on the virtual paper trading platform.